ReviewJournal of nanobiotechnology2026
Tumor microenvironment-responsive nanocarriers for enhanced glioblastoma immunotherapy.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The glioblastoma (GBM) microenvironment exhibits a profoundly immunosuppressive state, which constitutes the major barrier limiting the efficacy of immunotherapy. It is intricately intertwined with aberrant physicochemical characteristics including severe hypoxia, acidic pH, and redox imbalance. Although these physicochemical abnormalities further exacerbate immunosuppression within the GBM microenvironment, they also paradoxically serve as precise endogenous triggers for designing smart nanocarriers. By exploiting these pathological features as triggering signals, microenvironment-responsive nanocarriers can overcome the physical barriers imposed by the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), enabling precise delivery and on-demand release of immunomodulators at lesion site. Moreover, these nanocarriers can effectively alleviate immune tolerance by reprogramming tumor-associated immune cells or inducing immunogenic cell death, thereby remodeling the immunosuppressive GBM microenvironment. This review elucidates the physicochemical and immunosuppressive features of the GBM microenvironment. Furthermore, it systematically summarizes the design principles, cross-barrier targeting strategies, and immune remodeling mechanisms of responsive nanocarriers engineered upon tumor microenvironment (TME) characteristics. The analysis highlights the synergistic enhancement achieved through this paradigm: responding to TME signals to reverse immunosuppression. Finally, clinical translation challenges and future directions within this field are discussed to provide a comprehensive reference for designing highly efficient, GBM-targeted responsive nanoimmunotherapeutic platforms.
Indexed as
Identifiers
42482062What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.